Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2013
Effects of varenicline on abstinence and smoking reward following a programmed lapse.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 5 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Experimental manipulations of behavioral economic demand for addictive commodities: a meta-analysis.Addiction (Abingdon, England) · 2020Pooled it
- Behavioral economic tobacco demand in relation to cigarette consumption and nicotine dependence: a meta-analysis of cross-sectional relationships.Addiction (Abingdon, England) · 2019Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016Pooled it
- Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2015Pooled it
- Efficacy and safety of combination behavioral activation for smoking cessation and varenicline for treating tobacco dependence among individuals with current or past major depressive disorder: A 2 × 2 factorial, randomized, placebo-controlled trial.Addiction (Abingdon, England) · 2023Trial
- Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial.BMC medicine · 2023Trial
- The Blinded-Dose Purchase Task: assessing hypothetical demand based on cocaine, methamphetamine, and alcohol administration.Psychopharmacology · 2023Trial
- Effects of episodic future thinking on reinforcement pathology during smoking cessation treatment among individuals with substance use disorders.Psychopharmacology · 2022Trial
- Stressor-elicited smoking and craving during a smoking cessation attempt.Journal of psychopathology and clinical science · 2022Trial
- The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure.Psychopharmacology · 2021Trial
- Lower self-efficacy and greater depressive symptoms predict greater failure to recover from a single lapse cigarette.Journal of consulting and clinical psychology · 2020Trial
- Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders.Psychopharmacology · 2017Trial
- Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder.Schizophrenia research · 2017Trial
- Relative reinforcing efficacy of cigarettes as a predictor of smoking abstinence among treatment-seeking smokers.Psychopharmacology · 2016Trial
- An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers.The American journal of drug and alcohol abuse · 2015Trial
- The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement.Addictive behaviors · 2014Trial
- The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.Drug and alcohol dependence · 2013Trial
- Hypothetical food purchase tasks and eating behavior: A systematized review and future directions.Journal of the experimental analysis of behavior · 2026Review
- Human laboratory models of reward in substance use disorder.Pharmacology, biochemistry, and behavior · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionVarenicline (Chantix®) is an efficacious first-line medication for smoking cessation. Studies suggest that one mechanism by which varenicline facilitates sustained smoking abstinence is by reducing the likelihood of relapse to smoking when a lapse, or slip, occurs during a quit attempt. The present study extends this line of research by conducting a prospective laboratory study to examine the relapse prevention effects of varenicline following a programmed lapse.
methodsDaily smokers (N = 47) completed a 5-week outpatient study in which they were randomized to receive varenicline or placebo. The first week was a medication induction period that was immediately followed by a 4-week quit attempt. A programmed lapse (2 cigarettes smoked in the laboratory) occurred on the second day of the quit attempt.
resultsParticipants receiving varenicline were slower to relapse and had greater total abstinence rates following lapse exposure. Participants in the varenicline group rated lapse cigarettes lower on measures of reward and intoxication and showed increased behavioral economic demand elasticity for cigarettes (reduced cigarette purchasing at higher prices) compared with those receiving placebo.
conclusionsThese results demonstrate a relapse prevention effect of varenicline following smoking lapse exposure and suggest that an attenuation of reward from smoking and the blunting of subjective effects of smoking may underlie and/or contribute to this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.